EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|November 15, 2002
Winner By 'Webwhacker'
My wife and I are preparing to fly to Hong Kong and Singapore, where I will deliver some lectures. Naturally, we are trolling the Web to find information that will add pleasure and value to our journey.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
2
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
3
Tilrekimig Phase 2 Data Show EASI 75 Gains in Atopic Dermatitis
4
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
5